Dynamic Whole Body Positron Emission Tomography/Computed Tomography Imaging
NCT04017104 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 60
Last updated 2021-01-26
Summary
Quantitative parameters obtained with dynamic whole body imaging using positron emission tomography (PET) can provide additional and complementary information to standard PET. Dynamic imaging allows for better understanding of the behavior of the radio-pharmaceutical because it can be followed over time. Thought to be difficult to perform with currently available clinical equipment that can affect the clinical workflow, it has recently shown to be feasible. We want to test the feasibility of this imaging technique and evaluate its utility in identifying lesions with three different radio-pharmaceuticals as compared to standard static PET.
This study will also determine the clinical impact of DWB PET on participant management by comparing the overall qualitative assessment performed by nuclear medicine physicians between the standard PET images and the DWB ones.
Conditions
- Neuroendocrine Tumors
- Prostate Cancer
- Prostatic Neoplasms
- Carcinoid Tumor
- Paraganglioma
- Neuroblastoma
Interventions
- DIAGNOSTIC_TEST
-
18F-FDG PET/CT
For 18F-FDG as fasting period of 6 hours is required before the scan. Each study subject will have an intravenous catheter inserted. The subject will receive a bolus intravenous dose of the radiotracer from an approved study supplier site.The participant will rest in a comfortable chair for 20 minutes. The participant will then be taken to a designated washroom and asked to void prior to being scanned in order to clear excreted radiotracer activity from the urinary tract. The participant will then be taken to the PET/CT scanner. Subjects are positioned supine, arms down, and centered on the scanner bed and the PET/CT images will be acquired.
- DIAGNOSTIC_TEST
-
68Ga-DOTATOC PET/CT
Participants will not be encouraged to drink additional water due to the requirement to stay on the scanner for up to 90 minutes. There are no dietary restrictions. Each study subject will have an intravenous catheter inserted. The participants will then be taken to a designated washroom and asked to void, and will then be taken to the PET/CT scanner. A CT topogram will be acquired followed by very low dose whole body CT for attenuation correction and localization of PET emission data. The participant will receive a bolus intravenous dose of the radiotracer 68Ga-DOTATOC from an approved study supplier site. Simultaneously a 6 minute dynamic acquisition of the heart will be started, then followed by several whole body static acquisitions. After the DWB scan, participants may go to the washroom again and their vital signs will be recorded. After this, a new PET/CT acquisition, as specified in the 68Ga-DOTATOC PET/CT protocol, will immediately follow.
- DIAGNOSTIC_TEST
-
18F-DCFPyL PET/CT
Participants will not be encouraged to drink additional water due to the requirement to stay on the scanner for 90 minutes of the DWB acquisition. They will be unable to use the washroom during this time. As with the main study, participants will be instructed to fast for 4 hours prior to their appointment. Each study subject will have an intravenous catheter inserted. The participants will then be taken to a designated washroom and asked to void, and will then be taken to the PET/CT scanner. The participant will receive a bolus intravenous dose of 18F-DCFPyL from an approved supplier. This will then be followed by several whole body static acquisitions for a total scan time that will not be longer than 90 minutes. After the scan is finished, the participant will be allowed to rest in a comfortable chair or bed for 30 minutes. The participants will return to the scanner room and undergo the planned PET/CT imaging described in the main study.
Sponsors & Collaborators
-
British Columbia Cancer Agency
lead OTHER
Principal Investigators
-
Francois Benard, MD · BC Cancer
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2019-11-01
- Primary Completion
- 2022-08-01
- Completion
- 2024-08-01
Countries
- Canada
Study Locations
More Related Trials
-
PET CT Re-Planning NSCLC (4DCT-PET)
NCT03403127 ·Status: COMPLETED ·Phase: NA
-
Positron Emission Tomography/Magnetic Resonance Imaging in Patients
NCT01557881 ·Status: TERMINATED ·Phase: NA
-
Explore the Clinical Value of 68Ga-DOTANOC PET/CT and 18F-FDG PET/CT in Neuroendocrine Neoplasms
NCT03288597 ·Status: UNKNOWN
-
18F-LN1 PET/CT in Urothelial Carcinomas
NCT06120413 ·Status: RECRUITING
-
68Ga-DOTA-F2 PET/CT in Patients With Various Types of Cancer
NCT05637034 ·Status: UNKNOWN ·Phase: NA
-
Tumor Hypoxia With HX4 PET in Several Diseases
NCT02584400 ·Status: TERMINATED ·Phase: PHASE2
-
18FFDG PET/CT for Early Evaluation of Chemotherapy Efficacy in Metastatic Colic Adenocarcinoma
NCT05531045 ·Status: NOT_YET_RECRUITING
-
PET and/or MRI Scans in Assessing Tumor Response in Patients Receiving Antiangiogenesis Therapy
NCT00019565 ·Status: COMPLETED ·Phase: PHASE1
-
PET/CT Changes During Chemoimmunotherapy and Radiation Therapy in Patients With Stage IV Non-small Cell Lung Cancer
NCT04151940 ·Status: RECRUITING ·Phase: NA
-
Parametric Imaging in Positron Emission Tomography for Patient With Lung Cancer
NCT02821936 ·Status: COMPLETED ·Phase: NA
-
Study of the Fixation of Various Vectors in PET/CT in Patients With a With Lung Cancer Before and During of CRT or RT
NCT01261585 ·Status: COMPLETED
-
Prediction of Response to 2nd-line Hormone Therapy by FES CT/PET in Patients With Metastatic Breast Cancer
NCT03442504 ·Status: ACTIVE_NOT_RECRUITING ·Phase: NA
-
Assessment of 4D 18F-FDG PET-CT in Radiotherapy for Non Small Cell Lung Cancers
NCT01421953 ·Status: COMPLETED ·Phase: NA
-
Positron Emission Tomography Imaging With [F-18] FLT Compared to [F-18] FDG in Cancer Patients for Treatment Evaluation
NCT00894101 ·Status: WITHDRAWN ·Phase: PHASE2/PHASE3
-
18F-fluorocholine and 18F-fluoride PET in Prostate Cancer
NCT04340765 ·Status: COMPLETED ·Phase: NA
-
Evaluating the roLe of Multiplexed PET Imaging in the Detection and Staging of hepatocellulaR Carcinoma and gAstro-entero-pancreatic Tumors
NCT07178587 ·Status: RECRUITING ·Phase: NA
-
SUV on PSMA PET/CT in Non-Prostate Tumors
NCT03841760 ·Status: TERMINATED ·Phase: PHASE2
-
Role of PET Scan in the Evaluation of Early Response to Maintenance Treatment in Advanced Non-small-cell Lung Cancer
NCT02507518 ·Status: UNKNOWN ·Phase: PHASE2
-
Al18F-NOTA-octreotide PET Imaging in Neuroendocrine Tumors
NCT04552847 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
18F-AmBF3-TATE PET/CT for Imaging NET Patients
NCT04207762 ·Status: COMPLETED
-
Positron Emission Tomography for Detecting Non-small Cell Lung Cancer
NCT00004138 ·Status: COMPLETED ·Phase: NA
-
PET/CT Imaging Study With Simultaneous Dual-nuclide Imaging Technique
NCT06914427 ·Status: NOT_YET_RECRUITING ·Phase: NA
-
Positron Emission Tomography in Prostate Cancer
NCT00121212 ·Status: COMPLETED ·Phase: NA
-
TEP With 68-DOTANOC in Gastroenteropancreatic Neuroendocrine Tumors
NCT01747096 ·Status: COMPLETED ·Phase: NA
-
PET and MRI Imaging of Brain Tumors Using [18F]PARPi
NCT04173104 ·Status: COMPLETED ·Phase: EARLY_PHASE1